Skip to content

US · MNKD · BIOTECHNOLOGY

MannKind Corporation (MNKD) intrinsic value and stock valuation

$3.85as of 2026-11-21 · Mkt cap 1.27B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MannKind Corporation DCF and intrinsic value

InvestorsCraft values MNKD with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MNKD’s statements →

MannKind Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Danbury, CA 06810 mannkindcorp.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$349M+39.9% 5y CAGRd
20112025
Net income
$5.86M
20112025
Free cash flow
$13.7M
20112025
Total equity
-$-51.02M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$349M$285.5M$199M$99.8M$75.4M
Operating income$38.8M$72.6M$8.68M-$-64.11M-$-47.02M
Net income$5.86M$27.6M-$-11.94M-$-87.4M-$-80.93M
EPSd$18.7K$97.2K-$-44.72K-$-339.96K-$-324.71K
Operating cash flow$18.3M$42.5M$34.1M-$-80.7M-$-61.71M
Capital expenditure-$-4.57M-$-9.69M-$-42.44M-$-7.59M-$-11.47M
Free cash flow$13.7M$32.8M-$-8.35M-$-88.29M-$-73.17M
Total assets$792.2M$393.8M$475.2M$295.3M$321.2M
Total debt$473.4M$47.7M$272.6M$288.4M$289.2M
Net debt$398.5M$1.36M$34.1M$218.6M$165M
Total equity-$-51.02M-$-78.82M-$-246.17M-$-250.54M-$-209.35M
Cash and short-term investments$171.4M$197.3M$295.1M$170.9M$204.1M
Income statement
20252024202320222021
Revenue$349M$285.5M$199M$99.8M$75.4M
Cost of revenue$61.2M$76.6M$62.8M$57.5M$38.9M
Gross profit$287.8M$208.9M$136.2M$42.3M$36.6M
Research and development expenses$66.4M$45.9M$31.3M$19.7M$12.3M
Selling, general and administrative expenses$144.1M$94.3M$94.3M$91.5M$77.4M
Other expenses$38.5M-$-3.91M$1.92M-$-4.81M-$-6.12M
Operating expenses$249M$136.3M$127.5M$106.4M$83.6M
Cost and expenses$310.2M$212.9M$190.3M$163.9M$122.5M
Interest income$0.00$12.6M$6.15M$2.51M$110K
Interest expense$13.8M$38M$25.2M$24.8M$16.6M
Depreciation and amortization$12.3M$8.97M$4.54M$6.31M$3.24M
Ebitda$27.5M$77.5M$15.1M-$-56.32M-$-61.1M
Operating income$38.8M$72.6M$8.68M-$-64.11M-$-47.02M
Total other income/expenses, net-$-37.39M-$-42.07M-$-19.05M-$-23.29M-$-33.9M
Income before tax$1.41M$30.5M-$-10.38M-$-87.4M-$-80.93M
Income tax expense-$-4.46M$2.93M$1.56M$0.00$0.00
Net income$5.86M$27.6M-$-11.94M-$-87.4M-$-80.93M
Weighted average shares outstanding$305.6M$274.4M$267M$257.1M$249.2M
Weighted average diluted shares outstanding$314.1M$283.8M$267M$257.1M$249.2M
Balance sheet
20252024202320222021
Cash and short-term investments$171.4M$197.3M$295.1M$170.9M$204.1M
Net receivables$38.4M$11.8M$14.9M$16.8M$4.74M
Inventory$35.3M$27.9M$28.6M$21.8M$7.15M
Total current assets$291.6M$268.3M$373.4M$234.9M$219.5M
Property, plant and equipment, net$82.4M$85.4M$84.2M$45.1M$36.6M
Goodwill and intangible assets$72.7M$7.2M$3M$3.58M$0.00
Long-term investments$5.01M$5.48M$7.16M$1.96M$56.6M
Total non-current assets$500.6M$125.5M$101.8M$60.4M$101.7M
Total assets$792.2M$393.8M$475.2M$295.3M$321.2M
Accounts payable$9.03M$6.79M$9.58M$11.1M$6.96M
Short-term debt$49.2M$0.00$20M$9.56M$6.98M
Deferred revenue$15.3M$12.4M$9.09M$1.73M$830K
Total current liabilities$171M$81.8M$104.1M$67.3M$48.4M
Long-term debt$424.1M$47.7M$252.6M$278.8M$282.2M
Deferred revenue, non-current$40M$51.2M$69.8M$37.7M$24.5M
Total non-current liabilities$672.2M$390.8M$617.2M$478.5M$482.2M
Capital lease obligations$103.8M$11.6M$3.92M$5.34M$1.04M
Total liabilities$843.2M$472.7M$721.4M$545.8M$530.5M
Common stock$3.08M$3.03M$2.7M$2.64M$2.52M
Retained earnings-$-3.2B-$-3.2B-$-3.23B-$-3.22B-$-3.13B
Accumulated other comprehensive income (loss)$120K$1.11M$0.00$0.00$0.00
Total equity-$-51.02M-$-78.82M-$-246.17M-$-250.54M-$-209.35M
Total investments$101.5M$156.4M$63.8M$103M$136.6M
Total debt$473.4M$47.7M$272.6M$288.4M$289.2M
Net debt$398.5M$1.36M$34.1M$218.6M$165M
Cash flow statement
20252024202320222021
Net income$5.86M$27.6M-$-11.94M-$-87.4M-$-80.93M
Depreciation and amortization$12.3M$9.04M$5.8M$6.29M$5.47M
Stock-based compensation$24.2M$21.4M$17.7M$0.00$12.2M
Change in working capital-$-86.35M-$-36.47M$14.6M-$-24.05M-$-17.73M
Accounts receivable-$-4.76M$2.65M$2.35M-$-11.81M-$-780K
Inventory$10.4M-$-3.2M$4.57M-$-5.67M-$-4.08M
Accounts payable-$-16.71M-$-2.79M-$-1.47M$4.1M$1.37M
Net cash provided by operating activities$18.3M$42.5M$34.1M-$-80.7M-$-61.71M
Investments in property, plant and equipment-$-4.57M-$-9.69M-$-42.44M-$-7.59M-$-11.47M
Acquisitions, net-$-347.74M$0.00$0.00-$-15.34M-$-56.06M
Net cash used for investing activities-$-304.8M-$-96.65M-$-1.99M$4.87M-$-151.54M
Common stock issued$0.00-$-6.09M$6.89M$22.6M$1.89M
Common stock repurchased-$-3.26M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$315.1M-$-137.27M$136.6M$21.4M$270.3M
Net change in cash$28.6M-$-191.4M$168.7M-$-54.42M$57M
Cash at end of period$75.6M$47.1M$238.5M$69.8M$124.2M
Operating cash flow$18.3M$42.5M$34.1M-$-80.7M-$-61.71M
Capital expenditure-$-4.57M-$-9.69M-$-42.44M-$-7.59M-$-11.47M
Free cash flow$13.7M$32.8M-$-8.35M-$-88.29M-$-73.17M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MannKind Corporation

        MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

        CEO
        Michael E. Castagna
        Employees
        592
        Beta
        1.09

        Explore

        Frequently asked questions

        What is the intrinsic value of MannKind Corporation (MNKD)?

        MannKind Corporation (MNKD) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MNKD undervalued?

        MNKD trades at a price of $3.85 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.